Related Experiment Video
Updated: Apr 19, 2026
07:59
Acetylcholine Re-Challenge After Intracoronary Nitroglycerine Administration
Published on: April 4, 2022
1.9K
Beta-Blockers and Nitrates: Pharmacotherapy and Indications
Emanuela Facchini, Anna Degiovanni, Chiara Cavallino
1Coronary Care Unit and Catheterization Laboratory, "Maggiore della Carità" Hospital, Corso Mazzini 18, 28100 Novara, Italy. arognoni@hotmail.com.
Cardiovascular & Hematological Agents in Medicinal Chemistry
|December 30, 2014
Summary
Beta-blockers are first-line treatment for stable angina, while nitrates are second-line. This review evaluates their pharmacotherapy and indications for stable angina patients.
Area of Science:
- Pharmacology
- Cardiology
Background:
- Beta-blockers offer B1-selectivity, targeting cardiac receptors with minimal effects on bronchial and vascular receptors.
- Organic nitrates, though old, are vital for symptomatic coronary artery disease management.
- Chronic nitrate use may cause tolerance and endothelial dysfunction.
Purpose of the Study:
- To evaluate the pharmacotherapy and indications of beta-blockers and nitrates in stable angina.
- To highlight the clinical differences and applications of these anti-anginal agents.
Main Methods:
- Literature review of pharmacotherapy and clinical indications.
- Analysis of beta-blocker selectivity and nitrate side effects.
- Comparison of beta-blockers and nitrates as anti-anginal therapies.
Main Results:
- Beta-blockers are the primary therapy for stable angina without contraindications.
- Nitrates serve as a secondary therapy for angina symptom relief and prevention.
- Prognostic benefits of beta-blockers in stable angina require further documentation.
Conclusions:
- Beta-blockers and nitrates remain crucial in managing stable angina.
- Understanding their distinct properties and potential side effects is key for effective treatment.
- Further research is needed for chronic beta-blocker use in specific patient populations.
More Related Videos
Related Concept Videos
01:16Antianginal Drugs: Nitrates and β-Blockers
2.0K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
2.0K
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
2.0K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
2.0K
01:22Heart Failure Drugs: β-Blockers
1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
1.7K
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
1.7K
01:28Antihypertensive Drugs: Types of β-Blockers
2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
1.4K
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.4K